Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jan 07, 2024
Unmatched Trading Prowess: Tickeron's Top Robot Dominates with Over 70% Profitable Trades Amid Market Uncertainty!

Unmatched Trading Prowess: Tickeron's Top Robot Dominates with Over 70% Profitable Trades Amid Market Uncertainty!

Tickeron's quant team is thrilled to introduce the standout performer of the week, particularly noteworthy given the recent downturn in major stock indices. Despite the challenging market conditions, our quant team takes pride in highlighting the robot's exceptional achievement—delivering over 70% profitable signals for both long and short positions. This remarkable success can be attributed to its distinctive strategy, meticulously crafted to evaluate short-term trends in high-volatility stocks.

Swing Trader Pro: The Most Active Stocks with High Volatility (TA)

Click to view full description and closed trades for free!

 

Unleashing Precision Trading with Tickeron's AI Robot

Embark on a journey into the dynamic world of high-volatility stocks with our specially crafted AI Robot. Meticulously designed by Tickeron's expert quant team, this sophisticated algorithm blends classical and proprietary indicators to create a powerhouse for traders seeking maximum profitability.

Harnessing Mathematical Mastery for Daily Analysis

Our robot's mathematical prowess comes to life each day, meticulously analyzing short-term trends for individual stocks. The integration of machine learning algorithms ensures optimized parameters for each stock, enhancing the precision of trade signals and maximizing profits.

Strategic Trading Initiatives

Experience the agility of our robot as it strategically initiates trades based on signal strength. Depending on the quality of the signal, the robot can open multiple trades simultaneously, ensuring optimal profit extraction from the market's most effective signals.

Advanced Risk Management

Navigate the market with confidence through our advanced risk management system. A fixed limit take-profit order and a dynamic trailing stop algorithm work in tandem to safeguard your investments. The robot adapts in real-time to price dynamics, placing stop market orders strategically for optimal risk mitigation.

Experience Precision Trading with Advanced Technology. Don't Miss the Opportunity for the Ultimate Trading Excellence.

Here are the latest trades:

Related Ticker: EDIT, AEHR, EVGO, NIO, TLRY

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


EDIT in upward trend: price may jump up because it broke its lower Bollinger Band on September 09, 2026

EDIT may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 36 of 42 cases where EDIT's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 86%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 9 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +3.42% 3-day Advance, the price is estimated to grow further. Considering data from situations where EDIT advanced for three days, in 179 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.

The Aroon Indicator entered an Uptrend today. In 112 of 149 cases where EDIT Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 75%.

Bearish Trend Analysis

The 10-day RSI Indicator for EDIT moved out of overbought territory on August 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 28 similar instances where the indicator moved out of overbought territory. In 25 of the 28 cases, the stock moved lower in the following days. This puts the odds of a move lower at 89%.

The Momentum Indicator moved below the 0 level on September 09, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on EDIT as a result. In 80 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 90%.

The Moving Average Convergence Divergence Histogram (MACD) for EDIT turned negative on September 08, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 40 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 82%.

EDIT moved below its 50-day moving average on September 09, 2026 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for EDIT crossed bearishly below the 50-day moving average on September 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 11 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 73%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EDIT declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.939) is normal, around the industry mean (25.951). P/E Ratio (0.000) is within average values for comparable stocks, (40.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.265). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (5.855) is also within normal values, averaging (436.793).

The Tickeron Price Growth Rating for this company is 60 (best 1 - 100 worst), indicating fairly steady price growth. EDIT’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EDIT’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Moderna (NASDAQ:MRNA), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Nektar Therapeutics (NASDAQ:NKTR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.2B. The market cap for tickers in the group ranges from 58 to 128.84B. VRTX holds the highest valuation in this group at 128.84B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 5%. For the same Industry, the average monthly price growth was -7%, and the average quarterly price growth was 7%. PDSB experienced the highest price growth at 112%, while LGVN experienced the biggest fall at -65%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -5%. For the same stocks of the Industry, the average monthly volume growth was -35% and the average quarterly volume growth was -43%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 78
Price Growth Rating: 59
SMR Rating: 93
Profit Risk Rating: 92
Seasonality Score: -12 (-100 ... +100)
View a ticker or compare two or three
EDIT
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a company which translates genome editing technology into a novel class of human therapeutics

Industry Biotechnology

Profile
Details
Industry
Biotechnology
Address
11 Hurley Street
Phone
+1 617 401-9000
Employees
87
Web
https://www.editasmedicine.com
Interact to see
Advertisement
AngloGold Ashanti (AU) shares are tumbling approximately 11% in premarket trading on March 19, 2026, extending a steep multi-week correction that has now erased more than 35% of the stock's value from its March 2 peak of $129.14. The primary sustained catalyst driving the decline is AngloGold's lowered 2026 production guidance, projecting gold output of 2.80–3.17 million ounces — a mid-point decline versus the company's 2025 output of approximately 3.1 million ounces, and below analyst expectations.
CSIQ shares tumbled approximately 18% in premarket trading on March 19, 2026, following the release of deeply disappointing Q4 2025 earnings before the open. The company reported a net loss of $1.66 per diluted share, far worse than the Wall Street consensus estimate of -$0.98, representing a 69% earnings miss.
YRD shares are tumbling approximately 17% in premarket trading on March 19, 2026, from a prior close of $3.68 to approximately $3.05, following the company's release of Q4 and full-year 2025 financial results before the U.S. market open. Primary catalyst: A dramatic swing to net loss in Q4 2025. Yiren Digital reported a Q4 net loss of RMB 882.2 million (~USD 126.1 million), compared to net income of RMB 331.4 million in Q4 2024 — a more than $250 million deterioration year-over-year.
Shares of MU are down approximately 6.66% in premarket trading on March 19, 2026, sliding from a prior close of $461.73 to around $431.00. Despite a historic earnings beat — fiscal Q2 2026 revenue of $23.86 billion versus the $19.19 billion consensus, and adjusted EPS of $12.20 against an $8.79 estimate — the stock is experiencing a classic "sell the news" reaction.
NEM is trading approximately 9% lower in Thursday premarket, extending Wednesday's 4.56% session loss, as gold prices collapse following the Federal Reserve's hawkish policy hold. Gold spot prices fell 4.21% to $4,616.42 per ounce on March 19, marking the precious metal's sixth straight session of declines — its longest losing streak since late 2024.
Shares of VG are surging approximately +8% in Thursday's premarket session on March 19, 2026, with the stock trading near $16.04, up from the March 18 closing price of $14.85. The primary catalyst is a continuation of bullish momentum driven by a series of analyst price target upgrades, with Scotiabank most recently raising its target from $9 to $11.
LINC shares surged approximately +16% in premarket trading on March 19, 2026, reaching roughly $45.83 from a prior close of $39.51. Primary catalyst: Lincoln Educational Services is hosting its highly anticipated Investor Day today at its brand-new Nashville, TN campus, with presentations beginning at 10:00 am CT (11:00 am ET), live-streamed to investors globally.
PSLV is trading approximately 12% lower in premarket on March 19, 2026, tracking a violent selloff in silver futures. The Federal Reserve's hawkish hold on March 18 — keeping rates at 3.50%–3.75% while signaling fewer cuts ahead — was the primary macro trigger.
The Fed kept rates at 3.5–3.75% and signaled a “higher for longer” stance, with no urgency to cut and a willingness to tighten again if inflation stalls. This backdrop tends to favor quality growth, financials, energy, industrials, and health care, while pressuring long‑duration, leveraged sectors like speculative tech, small caps, utilities, and REITs.
PICS shares fell over 20% today, reversing much of their post‑IPO bounce and dropping well below the US$19 IPO price after initially trading in the mid‑US$15–16 range. The selloff followed PicPay’s Q4 and full‑year 2025 results, which showed strong revenue growth but highlighted thin margins, intense competition and ongoing execution risk in credit underwriting and payments.
RCAT shares fell over 16% today, dropping from recent levels near US$17 toward the mid‑US$14–15 range, after trading as high as US$18.78 in the past year and more than tripling from a 52‑week low of US$4.60.
HYMC shares fell over 13% today, sliding from the mid‑US$30s toward roughly US$31, after trading between US$2.30 and US$58.73 over the past 12 months and closing near US$39 just a few sessions ago.
USAS fell over 10% today, trading around US$5.83 by early afternoon from a previous close of US$6.55 — a one‑day decline of roughly 11% — as more than 5.9 million shares changed hands. The stock had surged earlier in 2026, with some data showing a move from about US$1.11 in March 2025 to over US$7.30 in mid‑March 2026 — a gain of more than 500% — leaving it vulnerable to profit‑taking.
CENX fell about 8.9% today, dropping US$4.94 to US$50.40 by midday, after closing at US$55.34 yesterday; shares now sit roughly 15% below their 52‑week high of US$59.12 but remain far above the 12‑month low of US$13.05. Q4 2025 results showed net sales of US$633.7 million and adjusted net income of US$128.2 million (US$1.25 per share), with adjusted EBITDA of US$170.6 million — a big sequential improvement — but GAAP net income was just US$1.8 million (US$0.02 per share), underscoring earnings volatility.
CNL shares fell over 8% today, trading down from around C$22.90 toward the low‑C$21s, after recently setting a new 1‑year high at C$28.99 on March 2 and gaining more than 70% over the past 12 months.
SMCI shares are plunging approximately 26% in Friday premarket trading, extending sharp after-hours losses from Thursday's session close of $30.79. The primary catalyst is a federal indictment unsealed March 19, 2026, charging three individuals associated with Super Micro — including a company co-founder — with conspiring to illegally export billions of dollars in AI server technology to China.
PL shares are surging approximately 19% in premarket trading on March 20, 2026, building on an 8.67% gain during the regular session on March 19. The primary catalyst is a blowout Q4 fiscal year 2026 earnings report released after the close on March 19, with quarterly revenue of $86.8 million — an 11.55% beat against consensus expectations of $77.81 million.
Unusual Machines (UMAC) is trading down approximately -8.60% in premarket on March 20, 2026, extending losses from the prior session. The primary catalyst is a proposed public stock offering announced after the market close on March 19, 2026, raising dilution concerns among investors.
FDX surged approximately 7% in premarket trading on March 20, 2026, moving from the prior session close of $356.11 to around $381. The primary catalyst is a blowout fiscal Q3 2026 earnings report, with adjusted EPS of $5.25 — beating Wall Street's consensus estimate of $4.13 by more than 27%.
Kingsoft Cloud Holdings Limited (KC) shares plunged about 9% in the most recent session, extending a sharp pullback after a recent rally. The selloff reflects mounting concerns around profitability, with the company still loss-making and showing weak multi-year revenue growth.